[Skip to nav](https://www.moffitt.org/research-science/researchers/frederick-locke#menu-mobile) [Skip to content](https://www.moffitt.org/research-science/researchers/frederick-locke#main-content)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/frederick-locke/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/frederick-locke/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate") Search
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/frederick-locke)
    * [ Cancers ](https://www.moffitt.org/cancers/)
      * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
      * [Acute Myelogenous Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myelogenous Leukemia \(AML\)")
      * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
      * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
      * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
      * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
      * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
      * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
      * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
      * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
      * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
      * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
      * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
      * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
      * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
      * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
      * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
      * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
      * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
      * [Chronic Myelogenous Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myelogenous Leukemia \(CML\)")
      * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
      * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
      * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
      * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
      * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
      * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
      * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
      * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
      * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
      * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
      * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
      * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
      * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
      * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
      * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
      * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
      * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
      * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
      * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
      * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
      * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
      * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
      * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
      * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
      * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
      * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
      * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
      * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
      * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
      * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
      * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
      * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
      * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
      * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
      * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
      * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
      * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
      * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
      * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
      * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
      * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
      * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
      * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
      * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
      * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
      * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
      * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
      * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
      * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
      * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
      * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
      * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
      * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
      * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
      * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
      * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
      * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
      * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
      * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
      * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
      * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")
    * [ Treatments ](https://www.moffitt.org/treatments/)
      * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
      * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
      * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
      * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
      * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
      * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
      * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
      * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
      * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
      * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
      * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
      * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
      * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
      * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
      * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
      * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
      * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
      * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
      * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
      * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
      * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
      * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")
    * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
      * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
      * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
      * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
      * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
      * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
      * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")
    * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/)
      * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
      * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
      * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
      * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
      * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
      * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")
    * [ ![](https://www.moffitt.org/contentassets/5f17f2115eca48a1aa7faa610608f778/clinical-trials.jpg) Search Clinical Trials  Moffitt participates in over 400 clinical trials. Find a trial that is right for you. ](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Search Clinical Trials")
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/frederick-locke)
    * [ Patient & Family ](https://www.moffitt.org/patient-family/)
    * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/)
      * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
      * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
      * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
      * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
      * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
      * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
      * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
      * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
      * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
      * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
      * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
      * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
      * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")
    * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/)
      * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
      * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
      * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
      * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
      * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
      * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
      * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
      * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
      * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
      * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")
    * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/)
      * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
      * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
      * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
      * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
      * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
      * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
      * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
      * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
      * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")
    * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/)
      * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
      * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
      * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
      * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
      * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
      * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
    * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/)
      * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")
    * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/)
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
      * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
      * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
      * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")
    * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/)
      * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
      * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
      * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
      * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")
    * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/)
      * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
      * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
      * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
      * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
      * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
      * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
      * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
      * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
      * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
      * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
      * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
      * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
      * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
      * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
      * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
      * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
      * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
      * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
      * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
      * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
      * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
      * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
      * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
      * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
      * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
      * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
      * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
      * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
      * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
      * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
      * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
      * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
      * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
      * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
      * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
      * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
      * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
      * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
      * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
      * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
      * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
      * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
      * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
      * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
      * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
      * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
      * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
      * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
      * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
      * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
      * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
      * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
      * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
      * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
      * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
      * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
      * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
      * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
      * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
      * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
      * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
      * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
      * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
      * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
      * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
      * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
      * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
      * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
      * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
      * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
      * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
      * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
      * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
      * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
      * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
      * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
      * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
      * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
      * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
      * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
      * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
      * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
      * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
      * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
      * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
      * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
      * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
      * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
      * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
      * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
      * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
      * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
      * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
      * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
      * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
      * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
      * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
      * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
      * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
      * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
      * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
      * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
      * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
      * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
      * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
      * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
      * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
      * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
      * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
      * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")
    * [ ![Friends supporting woman with cancer ](https://www.moffitt.org/globalassets/images/content-images/patient--family/women-cancer-640.jpg) Taking Care of Your Health  Taking Care of Your Health features cancer-related information, health tips, patient stories and more. ](https://www.moffitt.org/taking-care-of-your-health/ "Taking Care of Your Health")
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/frederick-locke)
    * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
    * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/)
      * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
      * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
      * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
      * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
      * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
      * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
      * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
      * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
      * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
      * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
      * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
      * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
      * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
      * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
      * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
      * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
      * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
      * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
      * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
      * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
      * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
      * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
      * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
      * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
      * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
      * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")
    * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
    * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/)
      * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
      * [Multidisciplinary Programs](https://www.moffitt.org/for-healthcare-professionals/continuing-education/multidisciplinary-programs/ "Multidisciplinary Programs")
      * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")
  * [Research](https://www.moffitt.org/research-science/researchers/frederick-locke)
    * [ Research Science ](https://www.moffitt.org/research-science/)
    * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/)
      * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
      * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
      * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
      * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
      * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")
    * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/)
      * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
      * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
      * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
      * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
      * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")
    * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/)
      * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
      * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")
    * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/)
      * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
      * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
      * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
      * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
      * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
      * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
      * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")
    * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/)
      * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
      * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
      * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
      * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
      * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
      * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
      * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
      * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
      * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
      * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
      * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
      * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
      * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")
    * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/)
      * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
      * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")
    * [ Administration ](https://www.moffitt.org/research-science/administration/)
      * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")
    * [ ![Research fellows in a lab](https://www.moffitt.org/contentassets/a7d26515856847ad8ebe488477e34948/research-training.jpg) Research Education and Training  We are interested in recruiting scholars who have a profound interest in preventing, treating and curing cancer. ](https://www.moffitt.org/education/research-education-and-training/ "Research Education and Training")
  * [Training & Education](https://www.moffitt.org/research-science/researchers/frederick-locke)
    * [ Education ](https://www.moffitt.org/education/)
    * [ Medical Education ](https://www.moffitt.org/education/medical-education/)
      * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
      * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
      * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
    * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/)
      * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
      * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
      * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
      * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
      * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
      * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
      * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
      * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")
    * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/)
      * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
      * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
      * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
      * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
      * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")
    * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/)
      * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
      * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
      * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
      * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
      * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
      * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
      * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
      * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
      * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
      * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
      * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
      * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
      * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
      * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
      * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
      * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
      * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
      * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
      * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
      * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
      * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
      * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
      * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
      * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")
    * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)
  * [Give](https://www.moffitt.org/research-science/researchers/frederick-locke)
    * [ Give ](https://www.moffitt.org/give/)
    * [ Why Give? ](https://www.moffitt.org/give/why-give/)
      * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
      * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
      * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
      * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
      * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
      * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")
    * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/)
      * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
      * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
      * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
      * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
      * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
      * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
      * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
      * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
      * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
      * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")
    * [ Get Involved ](https://www.moffitt.org/give/get-involved/)
      * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
      * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
      * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
      * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
      * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
      * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
      * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")
    * [ ![A researcher holds a Moffitt License Plate](https://www.moffitt.org/contentassets/fff003985b6341a8b2d684da79916350/ways-to-give.jpg) Ways to Give  Cancer touches all of us. Our mission - to contribute to the prevention and cure of cancer - depends on your support.  ](https://www.moffitt.org/give/ways-to-give/ "Ways to Give")


# Frederick Locke, MD
![Frederick  Locke](https://www.moffitt.org/globalassets/images/researchers_bio/LockeFrederick_7878.jpg)
Frederick Locke, MD 
Program Lead, Blood and Marrow Transplant and Cellular Immunotherapy 
Research Department Chair, Blood and Marrow Transplant and Cellular Immunotherapy 
Research Program Lead, Immuno-Oncology Program 
Program Co-Leader, Immuno-Oncology; Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy
**Program:** Blood and Marrow Transplant and Cellular Immunotherapy 
**Research Program:** Immuno-Oncology Program 
[Google Scholar Profile](https://scholar.google.com/citations?user=mfo2Xr0AAAAJ&hl=en)
[ Contact ](https://eforms.moffitt.org/ContactResearchersForm?PERID=7878)
  * ## Overview
Dr. Locke is focused on developing strategies to promote T cell responses against tumor associated antigens for patients with cancer.
### Associations
    * Blood and Marrow Transplant and Cellular Immunotherapy
    * Immunology
    * BioEngineering
    * Immuno-Oncology Program
    * Experimental Therapeutics Program
    * Center of Excellence for Evolutionary Therapy
### Education & Training
**Board Certification:**
**Fellowship:**
    * University of Chicago Medical Center - Hematology/Oncology
**Residency:**
    * Wayne State University/Detroit Medical Center - Internal Medicine
**Medical School:**
    * Wayne State University - MD
  * ## Research Interest
Dr. Locke is a physician and translational investigator specializing in the treatment of lymphoma and multiple myeloma in the Department of Blood and Marrow Transplantation at Moffitt. He is focused on developing strategies to promote T cell responses against tumor associated antigens for patients with these diseases and is the principal investigator for multiple cellular immunotherapy trials. He is a lead investigator for two national multi-center phase I/II studies treating aggressive lymphoma patients with anti-CD19 CAR T cells and the site PI of a randomized multi-center trial testing infusion of tumor (marrow) infiltrating lymphocytes for multiple myeloma. Dr. Locke’s translational research evaluates T cell responses against tumor associated antigens and neoantigens in myeloma patients. His findings justified a trial evaluating the biological activity of a unique Moffitt-created survivin dendritic cell vaccine using a novel schedule in conjunction with autologous transplant. Dr. Locke is the Chair of the Moffitt Cellular Therapy Advisory Committee and the Chair of the Moffitt Immunotherapy Working Group. In addition he is the Service Chief of the Moffitt Immune and Cellular Therapy (ICE-T) service, which was created to provide specialized clinical care for patients undergoing cellular immunotherapy treatments.
  * ## Participating Trials
[ Clinical Trial 19724 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-19724/ "Clinical Trial 19724")   
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release   
Condition: Malignant Hematology   
Status: Open 
[ Clinical Trial 20737 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-20737/ "Clinical Trial 20737")   
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release   
Condition: Malignant Hematology   
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()   
Status: Open 
[ Clinical Trial 21955 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21955/ "Clinical Trial 21955")   
Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma after Axicabtagene Ciloleucel   
Condition: Malignant Hematology   
Intervention: CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Tafasitamab ()   
Status: Open 
[ Clinical Trial 22080 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22080/ "Clinical Trial 22080")   
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma   
Condition: Malignant Hematology   
Intervention: Adriamycin (doxorubicin); Axicabtagene Ciloleucel (Yescarta); Etoposide (); Rituxan (rituximab); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); fludarabine (Fludarabine phosphate); prednisone (); rituximab ()   
Status: Open 
[ Clinical Trial 23184 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23184/ "Clinical Trial 23184")   
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy (CARIsMA)   
Condition: Malignant Hematology   
Intervention: Placebo ()   
Status: Open 
[ Clinical Trial 23363 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23363/ "Clinical Trial 23363")   
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3)   
Condition: Malignant Hematology   
Intervention: ALLO-647 (); Cema-cel (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)   
Status: Open 
[ Clinical Trial 23706 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23706/ "Clinical Trial 23706")   
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel   
Condition: Malignant Hematology   
Intervention: Axicabtagene Ciloleucel (Yescarta)   
Status: Open 
**If you believe you are eligible for one of these trials or studies, please call  
[813-745-6100](tel:+813-745-6100) or toll-free [1-800-679-0775](tel:+1-800-679-0775). **
  * ## Publications
    * Diamond B, Chahar D, Jain MD, Poos AM, Durante MA, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan KH, Jelinek T, Davies FE, Figura NB, Morgan GJ, Mai EK, Weisel K, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies. Blood Cancer Discov. 2025 Sep.6(5):450-463. Pubmedid: [40402512](https://www.ncbi.nlm.nih.gov/pubmed/40402512). Pmcid: PMC12405863. 
    * Locke FL, Le Gall JB, Fisher PW, Neelapu SS. Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching. J Clin Oncol. 2025 Sep.43(25):2834-2835. Pubmedid: [40549998](https://www.ncbi.nlm.nih.gov/pubmed/40549998). 
    * Hijazi A, Locke FL, Scholler N, Mattie M, Filosto S, Bedognetti D, Galon J. Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma. Clin Cancer Res. 2025 Sep.31(18):3834-3843. Pubmedid: [40622821](https://www.ncbi.nlm.nih.gov/pubmed/40622821). Pmcid: PMC12434396. 
    * Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: [40845845](https://www.ncbi.nlm.nih.gov/pubmed/40845845). 
    * Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Oct. Pubmedid: [41072416](https://www.ncbi.nlm.nih.gov/pubmed/41072416). 
    * Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD, Richard S, Martin T, Lin Y, Patel KK, Sidana S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 May.43(13):1597-1609. Pubmedid: [39965175](https://www.ncbi.nlm.nih.gov/pubmed/39965175). Pmcid: PMC12037312. 
    * Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Ouchveridze E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar AD, Liu Y, Locke FL, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Adv. 2025 May.9(9):2336-2340. Pubmedid: [40088469](https://www.ncbi.nlm.nih.gov/pubmed/40088469). Pmcid: PMC12127628. 
    * Balagurunathan Y, Choi JW, Thompson Z, Jain M, Locke FL. Radiomic Features Prognosticate Treatment Response in CAR-T Cell Therapy. Cancers (Basel). 2025 May.17(11). Pubmedid: [40507312](https://www.ncbi.nlm.nih.gov/pubmed/40507312). Pmcid: PMC12153729. 
    * Locke FL, Ball G, Ray MD, Li T, Limbrick-Oldfield EH, Popoff E, Kanters S. Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND. Hematol Oncol. 2025 May.43(3):e70100. Pubmedid: [40347097](https://www.ncbi.nlm.nih.gov/pubmed/40347097). Pmcid: PMC12065393. 
    * Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC. Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone Marrow Transplant. 2025 May.60(5):632-639. Pubmedid: [40025178](https://www.ncbi.nlm.nih.gov/pubmed/40025178). 
    * Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA, Miklos DB, Fisher PW, Feng A, Navale L, Le Gall JB, Neelapu SS. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. J Clin Oncol. 2025 May.43(14):1695-1705. Pubmedid: [39946666](https://www.ncbi.nlm.nih.gov/pubmed/39946666). Pmcid: PMC12058369. 
    * Faramand RG, Locke FL. Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL. Nat Rev Clin Oncol. 2025 Mar.22(3):161-162. Pubmedid: [39930262](https://www.ncbi.nlm.nih.gov/pubmed/39930262). 
    * Hoogland AI, Li X, Modi K, Welniak T, Rodriguez Y, Irizarry-Arroyo N, Oswald LB, Snider JT, Wade SW, Chavez J, Corallo S, Booth-Jones M, Jain MD, Locke FL, Jim HSL. Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene Ciloleucel. Transplant Cell Ther. 2025 Mar.31(3):157.e1-157.e13. Pubmedid: [39733840](https://www.ncbi.nlm.nih.gov/pubmed/39733840). 
    * Davila M, Lee SB, Kang YP, Boucher J, Mandula J, Roselli E, Chang D, Jimenez R, Kotani H, Reid K, Vazquez-Martinez J, Beatty N, Goala P, Sierra-Mondragon R, Liu M, Koomen J, Nguyen J, Hussaini M, Shaw T, Wang X, Faramand R, Jain M, Locke F, Rodriguez P, Sailer C, McSain S, Hamid S, Tariq M, Wang J, Abraham-Miranda J. CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma. Res Sq. 2025 Mar. Pubmedid: [40235478](https://www.ncbi.nlm.nih.gov/pubmed/40235478). Pmcid: PMC11998770. 
    * Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, Lin Y, Lunning MA, Hill BT, Ghobadi A, Hu ZH, Hemmer MT, Zoratti MJ, Vunnum S, Tsang J, Spooner C, Smith H, Fu C, Patel AR, Miao H, Shahani SA, Mirjah DL, Xu H, Pasquini MC. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 2025 Jun.9(11):2663-2676. Pubmedid: [39883946](https://www.ncbi.nlm.nih.gov/pubmed/39883946). Pmcid: PMC12155625. 
    * Locke FL, Mahmoudjafari Z, Kebriaei P, Gardner RA, Frigault MJ, Frey N, Komanduri KV, Perales MA, Nikiforow S. Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. Transplant Cell Ther. 2025 Jun.31(6):349.e1-349.e12. Pubmedid: [39954962](https://www.ncbi.nlm.nih.gov/pubmed/39954962). 
    * Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman M. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun.145(23):2762-2767. Pubmedid: [39938007](https://www.ncbi.nlm.nih.gov/pubmed/39938007). 
    * Patel AR, Kievit B, Hasegawa K, Ray M, Sharma R, Hofmann S, Blissett R, Locke FL. A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States. MDM Policy Pract. 2025 Jun.10(1). Pubmedid: [40575250](https://www.ncbi.nlm.nih.gov/pubmed/40575250). Pmcid: PMC12198509. 
    * Saha S, Rehman L, Rehman A, Darbaniyan F, Weber DM, Becnel M, Gaballa MR, Thomas SK, Lee HC, Chang CC, Arora R, Menges M, Corallo S, Davila ML, Locke FL, Tanner MR, Neelapu SS, Shpall EJ, Flowers CR, Orlowski RZ, Jenq RR, Jain MD, Peterson C, Hansen DK, Saini NY, Patel KK. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv. 2025 Jul.9(14):3429-3440. Pubmedid: [40198765](https://www.ncbi.nlm.nih.gov/pubmed/40198765). Pmcid: PMC12274813. 
    * Ahmed N, Thiruvengadam S, Hamadani M, Hu ZH, Grover NS, Shadman M, Locke FL, Gerson J, Frank MJ, Budde LE, Wang ML, Kim S, Bye M, Kharfan-Dabaja MA, Sauter CS, Hematti P, Turtle CJ, Ahmed S, Moskop A, Logan BR, Nunes A, Dalton DM, Kloos IM, Lee D, Xu H, Pasquini MC, Herrera AF. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025 Jul. Pubmedid: [40706035](https://www.ncbi.nlm.nih.gov/pubmed/40706035). 
    * Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD. Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2025 Jul.31(13):2756-2766. Pubmedid: [40238583](https://www.ncbi.nlm.nih.gov/pubmed/40238583). Pmcid: PMC12213223. 
    * Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma. Haematologica. 2025 Jul. Pubmedid: [40637727](https://www.ncbi.nlm.nih.gov/pubmed/40637727). 
    * Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul.31(7):419-433. Pubmedid: [40288610](https://www.ncbi.nlm.nih.gov/pubmed/40288610). 
    * Yu X, Jain MD, Menges MA, Cen L, Noble JD, Atkins R, Mohammad TJ, Bachmeier CA, Naderinezhad S, Reid K, Corallo S, Yoder SJ, Zhang C, Zhang L, Miranda JA, Shah B, Chavez JC, Hesterberg RS, Delgado LC, Savid-Frontera C, Rodriguez PC, Cleveland JL, Wang X, Davila ML, Locke FL. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. J Immunother Cancer. 2025 Jul.13(7). Pubmedid: [40730421](https://www.ncbi.nlm.nih.gov/pubmed/40730421). Pmcid: PMC12306477. 
    * Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jan.145(1):85-97. Pubmedid: [39365257](https://www.ncbi.nlm.nih.gov/pubmed/39365257). 
    * Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, Mishra A, Nieder M, Nishihori T, Hansen D, Jain M, Lazaryan A, Perez L, Pidala J, Locke F, Anasetti C, Bejanyan N, Elmariah H. Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients. Cancers (Basel). 2025 Jan.17(2). Pubmedid: [39858092](https://www.ncbi.nlm.nih.gov/pubmed/39858092). Pmcid: PMC11763395. 
    * Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ. Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer. 2025 Feb.13(2). Pubmedid: [39924174](https://www.ncbi.nlm.nih.gov/pubmed/39924174). Pmcid: PMC11808862. 
    * Locke FL, Westin JR, To C. Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphoma. Future Oncol. 2025 Feb.21(4):393-407. Pubmedid: [39800964](https://www.ncbi.nlm.nih.gov/pubmed/39800964). Pmcid: PMC11813213. 
    * Tian Y, Budka J, Locke FL, Westin JR, To C, Tiwari G, Mao D, Bedognetti D, Shen RR, Andrade J, Filosto S. Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). Front Oncol. 2025 Feb.15:1519473. Pubmedid: [40083872](https://www.ncbi.nlm.nih.gov/pubmed/40083872). Pmcid: PMC11903469. 
    * Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, Bücklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini MC, Raj SS, Rajeeve S, Salles GA, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid OB, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025 Aug.146(7):834-846. Pubmedid: [40258181](https://www.ncbi.nlm.nih.gov/pubmed/40258181). 
    * Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Aug. Pubmedid: [40754223](https://www.ncbi.nlm.nih.gov/pubmed/40754223). 
    * Freeman CL, Abraham-Miranda J, Menges M, Atkins RM, Noble J, Liu H, Corallo S, Cuadrado Delgado LA, Ribickas AJ, Savid-Frontera C, de Avila G, Castaneda Puglianini OA, Ochoa-Bayona J, Hansen DK, Alsina M, Baz R, Nishihori T, Shain KH, Locke FL. Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma. Mol Ther. 2025 Aug.33(8):3576-3589. Pubmedid: [40253586](https://www.ncbi.nlm.nih.gov/pubmed/40253586). Pmcid: PMC12461620. 
    * Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen AF, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Ramakrishnan Geethakumari P, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse CS, Turtle CJ, Valluripalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror ML. New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma. Blood Adv. 2025 Aug. Pubmedid: [40811818](https://www.ncbi.nlm.nih.gov/pubmed/40811818). 
    * Winkelmann M, Raj SS, Jain MD, Iacoboni G, Müller F, Hansmann L, Corona M, Luna A, Jhaveri K, Shah GL, Scordo M, Mohammad T, Dean EA, Sheikh GT, Kunz WG, Tix T, Bücklein VL, Bedmutha A, Leithner D, von Bergwelt-Baildon M, Boardman AP, Palomba ML, Park JH, Salles G, Perales MA, Schöder H, Subklewe M, Barba P, Locke FL, Shouval R, Rejeski K. Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma. Blood Cancer J. 2025 Aug.15(1):144. Pubmedid: [40858552](https://www.ncbi.nlm.nih.gov/pubmed/40858552). Pmcid: PMC12381142. 
    * Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, Corallo S, De Avila G, Freeman C, Gonzalez R, Grajales-Cruz A, Harvey K, Liu HD, Nishihori T, Oliveira GH, Oswald LB, Castaneda Puglianini O, Selvakumar S, Sharma AB, Wang E, Shain KH, Jain M, Locke FL, Alomar M, Hansen DK, Lee DH. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025 Apr.15(1):63. Pubmedid: [40229239](https://www.ncbi.nlm.nih.gov/pubmed/40229239). Pmcid: PMC11997198. 
    * Mokhtari S, Asquith JM, Kareem SS, Bachmeier CA, Pina Y, Faramand RG, Kim Y, Peguero EN, Sahebjam S, Jaffer MH, Iacono DP, Jain MD, Vogelbaum MA, Davila ML, Forsyth PA, Locke FL, Lazaryan A. Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Int J Mol Sci. 2025 Apr.26(8). Pubmedid: [40332772](https://www.ncbi.nlm.nih.gov/pubmed/40332772). Pmcid: PMC12028060. 
    * Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: [39652773](https://www.ncbi.nlm.nih.gov/pubmed/39652773). 
    * Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, Shah BD, Chavez J, Bello C, Lazaryan A, Khimani F, Ibarz JP, Liu HD, Locke FL, Jain MD, Zhang L, Kharfan-Dabaja MA, Kim J, Ayala E, Nishihori T, Sokol L. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma. Transplant Cell Ther. 2024 Sep.30(9):887.e1-887.e9. Pubmedid: [38740140](https://www.ncbi.nlm.nih.gov/pubmed/38740140). 
    * Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct.42(30):3581-3592. Pubmedid: [39094076](https://www.ncbi.nlm.nih.gov/pubmed/39094076). Pmcid: PMC11483191. 
    * Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Sireesha Asoori, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024 Oct.14(1):180. Pubmedid: [39414769](https://www.ncbi.nlm.nih.gov/pubmed/39414769). Pmcid: PMC11484697. 
    * Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, Baluch A, Febres-Aldana AJ, Alsina M, Elmariah H, Khimani F, Hansen DK, Freeman CL, Jain MD, Locke F, Lazaryan A, Liu HD, Mishra A, Mirza AS, Nishihori T, Ochoa L, Perez L, Pidala J, Puglianini OC, Nieder M, Perna F, Kim J, Bejanyan N, Faramand R. Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. Open Forum Infect Dis. 2024 Oct.11(10):ofae564. Pubmedid: [39411216](https://www.ncbi.nlm.nih.gov/pubmed/39411216). Pmcid: PMC11475747. 
    * Balagurunathan Y, Wei Z, Qi J, Thompson Z, Dean E, Lu H, Vardhanabhuti S, Corallo S, Choi JW, Kim JJ, Mattie M, Jain M, Locke FL. Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy. Front Oncol. 2024 Nov.14:1485039. Pubmedid: [39659779](https://www.ncbi.nlm.nih.gov/pubmed/39659779). Pmcid: PMC11629080. 
    * Diamond B, Chahar D, Jain MD, Poos AM, Durante M, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan K, Jelinek T, Davies F, Figura NB, Morgan G, Mai E, Weisel KC, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies. bioRxiv. 2024 Nov. Pubmedid: [39605649](https://www.ncbi.nlm.nih.gov/pubmed/39605649). Pmcid: PMC11601314. 
    * Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplant Cell Ther. 2024 Nov.30(11):1065-1079. Pubmedid: [39187161](https://www.ncbi.nlm.nih.gov/pubmed/39187161). 
    * Di Staso R, Casadei B, Locke FL, Jain M, Voorhees TJ, Kittai AS, Bastos-Oreiro M, Gutiérrez A, Martin Garcia-Sancho A, Terol MJ, Mead M, Maranzano MJ, Iacoboni G, Barba P, Kwon M, Bailen R, Reguera-Ortega JL, Mian A, Hill B, Bachy E, Morschhauser F, Houot R, Thieblemont C, Le Gouill S, Masetti R, Gori D, Broccoli A, Zinzani PL, Argnani L. Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma. Blood Cancer J. 2024 Nov.14(1):197. Pubmedid: [39511146](https://www.ncbi.nlm.nih.gov/pubmed/39511146). Pmcid: PMC11544145. 
    * Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024 May.109(5):1514-1524. Pubmedid: [37855036](https://www.ncbi.nlm.nih.gov/pubmed/37855036). Pmcid: PMC11063864. 
    * Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May.99(5):880-889. Pubmedid: [38504387](https://www.ncbi.nlm.nih.gov/pubmed/38504387). 
    * Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar.5(2):106-113. Pubmedid: [38194367](https://www.ncbi.nlm.nih.gov/pubmed/38194367). Pmcid: PMC10905320. 
    * Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: [38123069](https://www.ncbi.nlm.nih.gov/pubmed/38123069). 
    * Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 Mar.109(3):777-786. Pubmedid: [37731379](https://www.ncbi.nlm.nih.gov/pubmed/37731379). Pmcid: PMC10905101. 
    * Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: [37723045](https://www.ncbi.nlm.nih.gov/pubmed/37723045). 
    * Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024 Jun.143(26):2722-2734. Pubmedid: [38635762](https://www.ncbi.nlm.nih.gov/pubmed/38635762). Pmcid: PMC11251200. 
    * Chavez JC, Grajales A, Sandoval-Sus J, Turba E, Nodzon L, Uriepero-Palma A, Ammad-Ud-Din M, Sahakian E, Komrokji R, Sokol L, Locke FL, Shah B, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Bello C, Pinilla-Ibarz J. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis. Clin Lymphoma Myeloma Leuk. 2024 Jun.24(6):382-391.e2. Pubmedid: [38508880](https://www.ncbi.nlm.nih.gov/pubmed/38508880). 
    * Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024 Jun.17(1):42. Pubmedid: [38845015](https://www.ncbi.nlm.nih.gov/pubmed/38845015). Pmcid: PMC11157748. 
    * Oluwole OO, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S, Patel AR, Locke FL. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert Rev Anticancer Ther. 2024 Jun.24(6):457-465. Pubmedid: [38646700](https://www.ncbi.nlm.nih.gov/pubmed/38646700). 
    * Locke FL, Oluwole OO, Kuruvilla J, Thieblemont C, Morschhauser F, Salles GA, Rowe SP, Vardhanabhuti S, Winters J, Filosto S, To C, Cheng P, Schupp M, Korn R, Kersten MJ. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood. 2024 Jun.143(24):2464-2473. Pubmedid: [38557775](https://www.ncbi.nlm.nih.gov/pubmed/38557775). Pmcid: PMC11208295. 
    * Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk JP, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Adv. 2024 Jun.8(11):2982-2990. Pubmedid: [38315832](https://www.ncbi.nlm.nih.gov/pubmed/38315832). Pmcid: PMC11302377. 
    * Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: [37855718](https://www.ncbi.nlm.nih.gov/pubmed/37855718). 
    * Oluwole OO, Ray MD, Davies N, Bradford R, Jones C, Patel AR, Locke FL. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results. J Med Econ. 2024 Jan.27(1):230-239. Pubmedid: [38240256](https://www.ncbi.nlm.nih.gov/pubmed/38240256). 
    * Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2024 Feb.30(2):229.e1-229.e11. Pubmedid: [37952648](https://www.ncbi.nlm.nih.gov/pubmed/37952648). 
    * Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill BT, Lee C, Zinzani PL, Kröger N, López-Guillermo A, Greinix H, Zhang W, Tiwari G, Budka J, Marincola FM, To C, Mattie M, Schupp M, Cheng P, Bot A, Shen R, Bedognetti D, Miao H, Galon J. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024 Feb.30(2):507-518. Pubmedid: [38233586](https://www.ncbi.nlm.nih.gov/pubmed/38233586). Pmcid: PMC10878966. 
    * Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, Nikiforow S, Hashmi H, Mooney K, Bhaskar ST, Morris K, Gatwood K, Baer B, Anderson LD, Hamadani M. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024 Feb.30(2):131-142. Pubmedid: [37951502](https://www.ncbi.nlm.nih.gov/pubmed/37951502). 
    * Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning MA, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb.8(4):1042-1050. Pubmedid: [38051550](https://www.ncbi.nlm.nih.gov/pubmed/38051550). Pmcid: PMC10920102. 
    * Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 Feb.30(2):338-341. Pubmedid: [38195751](https://www.ncbi.nlm.nih.gov/pubmed/38195751). 
    * Hoogland AI, Barata A, Li X, Irizarry-Arroyo N, Jain MD, Welniak T, Rodriguez Y, Oswald LB, Gudenkauf LM, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Crowder SL, Parker NH, Carson TL, Vinci CE, Pidala JA, Logue J, Locke FL, Jim HSL. Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024 Dec.30(12):1219.e1-1219.e11. Pubmedid: [39306278](https://www.ncbi.nlm.nih.gov/pubmed/39306278). Pmcid: PMC11635818. 
    * Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson L, Fererri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transplant Cell Ther. 2024 Aug.30(8):790.e1-790.e16. Pubmedid: [38834151](https://www.ncbi.nlm.nih.gov/pubmed/38834151). 
    * Gardner RA, White C, Elsallab M, Farnia S, Fraint E, Grilley B, Bateman-House A, Grupp SA, Kenderian S, Locke FL, Nikiforow S, Oluwole OO, Rouce RH, Spiegel J, Shah NN, Sharma A, Komanduri K, Gill S. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies. Transplant Cell Ther. 2024 Aug.30(8):776-787. Pubmedid: [38762057](https://www.ncbi.nlm.nih.gov/pubmed/38762057). Pmcid: PMC11296902. 
    * Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024 Aug.17(1):61. Pubmedid: [39107847](https://www.ncbi.nlm.nih.gov/pubmed/39107847). Pmcid: PMC11305039. 
    * Perna F, Parekh S, Diorio C, Smith M, Subklewe M, Mehta R, Locke FL, Shah NN. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. Blood Adv. 2024 Aug.8(16):4348-4358. Pubmedid: [38861351](https://www.ncbi.nlm.nih.gov/pubmed/38861351). Pmcid: PMC11375260. 
    * Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge WA, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024 Apr.8(8):1857-1868. Pubmedid: [38181508](https://www.ncbi.nlm.nih.gov/pubmed/38181508). Pmcid: PMC11007437. 
    * Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024 Apr.14(1):63. Pubmedid: [38609386](https://www.ncbi.nlm.nih.gov/pubmed/38609386). Pmcid: PMC11015040. 
    * Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: [37835405](https://www.ncbi.nlm.nih.gov/pubmed/37835405). Pmcid: PMC10571575. 
    * Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel Iv O, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 2023 Sep.8(18). Pubmedid: [37581943](https://www.ncbi.nlm.nih.gov/pubmed/37581943). Pmcid: PMC10561731. 
    * Freeman CL, Locke FL. CARs put age in the rearview mirror. Blood. 2023 Sep.142(12):1029-1031. Pubmedid: [37733380](https://www.ncbi.nlm.nih.gov/pubmed/37733380). 
    * Westin JR, To C, Locke FL. Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply. N Engl J Med. 2023 Sep.389(12):1152-1153. Pubmedid: [37733323](https://www.ncbi.nlm.nih.gov/pubmed/37733323). 
    * Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep.9(38):eadg3919. Pubmedid: [37738350](https://www.ncbi.nlm.nih.gov/pubmed/37738350). Pmcid: PMC10516499. 
    * Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 Sep.29(9):548-555. Pubmedid: [37419325](https://www.ncbi.nlm.nih.gov/pubmed/37419325). 
    * Ibrahim U, Bassil C, Chavez JC, Khimani F, Jain MD, Locke FL, Lazaryan A, Osman K. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease. Clin Lymphoma Myeloma Leuk. 2023 Oct.23(10):772-778. Pubmedid: [37263876](https://www.ncbi.nlm.nih.gov/pubmed/37263876). 
    * Akhtar OS, Cao B, Wang X, Torka P, Al-Jumayli M, Locke FL, Freeman CL. CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response. Blood Adv. 2023 Oct.7(19):5937-5940. Pubmedid: [37236167](https://www.ncbi.nlm.nih.gov/pubmed/37236167). Pmcid: PMC10562759. 
    * Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clin Cancer Res. 2023 Nov.29(22):4575-4585. Pubmedid: [37735756](https://www.ncbi.nlm.nih.gov/pubmed/37735756). 
    * Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bücklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov.98(11):1699-1710. Pubmedid: [37584447](https://www.ncbi.nlm.nih.gov/pubmed/37584447). Pmcid: PMC10659121. 
    * Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023 May.41(14):2594-2606. Pubmedid: [36753699](https://www.ncbi.nlm.nih.gov/pubmed/36753699). 
    * Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clin Cancer Res. 2023 May.29(10):1894-1905. Pubmedid: [36999993](https://www.ncbi.nlm.nih.gov/pubmed/36999993). Pmcid: PMC10183830. 
    * Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023 May.141(20):2460-2469. Pubmedid: [36800563](https://www.ncbi.nlm.nih.gov/pubmed/36800563). 
    * Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, Goy A, McSweeney P, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 May.141(19):2307-2315. Pubmedid: [36821768](https://www.ncbi.nlm.nih.gov/pubmed/36821768). 
    * Dong N, Lopes-Garcia LR, Viñal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun.29(6):349.e1-349.e8. Pubmedid: [36878427](https://www.ncbi.nlm.nih.gov/pubmed/36878427). 
    * Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul.16(1):88. Pubmedid: [37525244](https://www.ncbi.nlm.nih.gov/pubmed/37525244). Pmcid: PMC10391746. 
    * Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul.389(2):148-157. Pubmedid: [37272527](https://www.ncbi.nlm.nih.gov/pubmed/37272527). 
    * Barata A, Hoogland AI, Small BJ, Locke FL, Jim HSL. Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?. Transplant Cell Ther. 2023 Jan.29(1):65. Pubmedid: [36179988](https://www.ncbi.nlm.nih.gov/pubmed/36179988). 
    * Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023 Jan.41(3):555-567. Pubmedid: [35658525](https://www.ncbi.nlm.nih.gov/pubmed/35658525). Pmcid: PMC9870225. 
    * Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 Jan.108(1):98-109. Pubmedid: [35833303](https://www.ncbi.nlm.nih.gov/pubmed/35833303). Pmcid: PMC9827150. 
    * Lee DH, Jain M, Lazaryan A, Locke FL, Jeong D, Alomar M. Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma. JACC Case Rep. 2023 Feb.8:101634. Pubmedid: [36860560](https://www.ncbi.nlm.nih.gov/pubmed/36860560). Pmcid: PMC9969540. 
    * Kirtane K, Reblin M, Oswald LB, Irizarry-Arroyo N, McCormick R, Locke FL, Ketcher D. Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time. Leuk Lymphoma. 2023 Feb.64(2):364-370. Pubmedid: [36416677](https://www.ncbi.nlm.nih.gov/pubmed/36416677). Pmcid: PMC10329860. 
    * Choi JW, Dean EA, Lu H, Thompson Z, Qi J, Krivenko G, Jain MD, Locke FL, Balagurunathan Y. Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers. Front Immunol. 2023 Feb.14:994520. Pubmedid: [36875072](https://www.ncbi.nlm.nih.gov/pubmed/36875072). Pmcid: PMC9975754. 
    * Khaled ML, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace GC, Evernden B, Ospina OE, Hall M, Liu M, Darville LNF, Izumi V, Chen YA, Pilon-Thomas S, Stewart PA, Koomen JM, Corallo SA, Jain MD, Robinson TJ, Locke FL, Forsyth PA, Smalley I. Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease. bioRxiv. 2023 Dec. Pubmedid: [38187773](https://www.ncbi.nlm.nih.gov/pubmed/38187773). Pmcid: PMC10769272. 
    * Johnson GA, Locke FL. Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy. Hematol Oncol Clin North Am. 2023 Dec.37(6):1189-1199. Pubmedid: [37580193](https://www.ncbi.nlm.nih.gov/pubmed/37580193). 
    * Blue B, Alomar M, Locke FL. Guarding the Heart in an Era of "Tachy-CAR-T": The Rapid Proliferation of a Transformative Therapy. JACC CardioOncol. 2023 Dec.5(6):755-757. Pubmedid: [38204996](https://www.ncbi.nlm.nih.gov/pubmed/38204996). Pmcid: PMC10774745. 
    * Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program. 2023 Dec.2023(1):198-208. Pubmedid: [38066881](https://www.ncbi.nlm.nih.gov/pubmed/38066881). Pmcid: PMC10727074. 
    * Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: [37307173](https://www.ncbi.nlm.nih.gov/pubmed/37307173). Pmcid: PMC10424134. 
    * Dean EA, Kimmel GJ, Frank MJ, Bukhari A, Hossain NM, Jain MD, Dahiya S, Miklos DB, Altrock PM, Locke FL. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2023 Aug.7(16):4608-4618. Pubmedid: [37126659](https://www.ncbi.nlm.nih.gov/pubmed/37126659). Pmcid: PMC10448428. 
    * Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug.13(1):117. Pubmedid: [37558706](https://www.ncbi.nlm.nih.gov/pubmed/37558706). Pmcid: PMC10412575. 
    * Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. Hemasphere. 2023 Aug.7(8):e907. Pubmedid: [37449196](https://www.ncbi.nlm.nih.gov/pubmed/37449196). Pmcid: PMC10337711. 
    * Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr.9(1):18. Pubmedid: [37005652](https://www.ncbi.nlm.nih.gov/pubmed/37005652). Pmcid: PMC10067156. 
    * Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 Apr.41(11):2087-2097. Pubmedid: [36623248](https://www.ncbi.nlm.nih.gov/pubmed/36623248). Pmcid: PMC10082273. 
    * Lee D, Jordan AI, Menges MA, Lazaryan A, Nishihori T, Gaballa SR, Shah BD, Pinilla-Ibarz J, Baluch A, Klinkova OV, Chavez JC, Jain MD, Locke FL. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Transplant Cell Ther. 2023 Apr.29(4):277.e1-277.e9. Pubmedid: [35970303](https://www.ncbi.nlm.nih.gov/pubmed/35970303). 
    * Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 Apr.29(4):906-916. Pubmedid: [36914893](https://www.ncbi.nlm.nih.gov/pubmed/36914893). Pmcid: PMC10121864. 
    * Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations. Transplant Cell Ther. 2023 Apr.29(4):228-239. Pubmedid: [36709800](https://www.ncbi.nlm.nih.gov/pubmed/36709800). 
    * Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 Sep.3(5):385-393. Pubmedid: [35533245](https://www.ncbi.nlm.nih.gov/pubmed/35533245). Pmcid: PMC9445749. 
    * Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022 Sep.28(9):581.e1-581.e8. Pubmedid: [35609867](https://www.ncbi.nlm.nih.gov/pubmed/35609867). Pmcid: PMC9427701. 
    * Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022 Sep.28(9):1872-1882. Pubmedid: [36038629](https://www.ncbi.nlm.nih.gov/pubmed/36038629). Pmcid: PMC9499856. 
    * Abraham-Miranda J, Menges M, Atkins R, Mattie M, Kanska J, Turner J, Hidalgo-Vargas MJ, Locke FL. CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production. Front Immunol. 2022 Sep.13:1007042. Pubmedid: [36225930](https://www.ncbi.nlm.nih.gov/pubmed/36225930). Pmcid: PMC9549966. 
    * Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 Oct.22(10):753-759. Pubmedid: [35780055](https://www.ncbi.nlm.nih.gov/pubmed/35780055). 
    * Ghobadi A, Slade M, Kantarjian HM, Alvarenga J, Aldoss I, Mohammed K, Jabbour EJ, Faramand RG, Shah BD, Locke FL, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 Nov.140(20):2101-2112. Pubmedid: [35877996](https://www.ncbi.nlm.nih.gov/pubmed/35877996). 
    * Oswald LB, Li X, Carvajal R, Hoogland AI, Gudenkauf LM, Hansen DK, Alsina M, Locke FL, Rodriguez Y, Irizarry-Arroyo N, Robinson EJ, Jim HSL, Gonzalez BD, Kirtane K. Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. Cancers (Basel). 2022 May.14(11). Pubmedid: [35681722](https://www.ncbi.nlm.nih.gov/pubmed/35681722). Pmcid: PMC9179384. 
    * Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022 May.10(5). Pubmedid: [35580927](https://www.ncbi.nlm.nih.gov/pubmed/35580927). Pmcid: PMC9114843. 
    * Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi P, Beitinjaneh A, Reagan P, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022 Mar.139(9):1330-1339. Pubmedid: [34570879](https://www.ncbi.nlm.nih.gov/pubmed/34570879). Pmcid: PMC8900276. 
    * Hoogland AI, Barata A, Logue J, Kommalapati A, Hyland KA, Nelson AM, Eisel SL, Small BJ, James BW, Christy SM, Bulls HW, Booth-Jones M, Jayani RV, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 Jun.28(6):305.e1-305.e9. Pubmedid: [35378330](https://www.ncbi.nlm.nih.gov/pubmed/35378330). Pmcid: PMC9197947. 
    * Cheng R, Scippa K, Locke FL, Snider JT, Jim H. Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study. Oncol Ther. 2022 Jun.10(1):123-141. Pubmedid: [34778941](https://www.ncbi.nlm.nih.gov/pubmed/34778941). Pmcid: PMC8590924. 
    * Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, Jain MD. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Adv. 2022 Jul.6(13):3970-3973. Pubmedid: [35816359](https://www.ncbi.nlm.nih.gov/pubmed/35816359). Pmcid: PMC9278282. 
    * Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplant Cell Ther. 2022 Jul.28(7):401.e1-401.e7. Pubmedid: [35580732](https://www.ncbi.nlm.nih.gov/pubmed/35580732). Pmcid: PMC9339228. 
    * Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: [34649279](https://www.ncbi.nlm.nih.gov/pubmed/34649279). Pmcid: PMC8753213. 
    * Hamadani M, Gopal AK, Pasquini MC, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea SO, Gauthier J, Agrawal V, Grover NS, Lekakis LJ, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022 Jan.6(2):486-494. Pubmedid: [34673903](https://www.ncbi.nlm.nih.gov/pubmed/34673903). Pmcid: PMC8791562. 
    * Oluwole OO, Liu R, Diakite I, Feng C, Patel A, Nourhussein I, Snider JT, Locke FL. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. J Med Econ. 2022 Jan.25(1):541-551. Pubmedid: [35443867](https://www.ncbi.nlm.nih.gov/pubmed/35443867). 
    * Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 Feb.386(7):640-654. Pubmedid: [34891224](https://www.ncbi.nlm.nih.gov/pubmed/34891224). 
    * Kimmel GJ, Locke FL, Altrock PM. Correction to 'The roles of T-cell competition and stochastic extinction events in CAR T-cell therapy'. Proc Biol Sci. 2022 Feb.289(1968):20212786. Pubmedid: [35135356](https://www.ncbi.nlm.nih.gov/pubmed/35135356). Pmcid: PMC8826130. 
    * Sheikh S, Mokhtari S, Silverman JA, Reid K, Faramand R, Davila ML, Franke N, Locke FL, Jain MD, Wong D, Kuruvilla JG. Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem. 2022 Feb.3(1):223-227. Pubmedid: [35846190](https://www.ncbi.nlm.nih.gov/pubmed/35846190). Pmcid: PMC9175700. 
    * Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec.28(12):829.e1-829.e8. Pubmedid: [36174934](https://www.ncbi.nlm.nih.gov/pubmed/36174934). Pmcid: PMC9791940. 
    * Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: [35939783](https://www.ncbi.nlm.nih.gov/pubmed/35939783). Pmcid: PMC9768247. 
    * Oluwole OO, Chen JMH, Chan K, Patel AR, Jansen JP, Keeping S, Zheng Y, Snider JT, Locke FL. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2022 Dec.63(13):3052-3062. Pubmedid: [36048026](https://www.ncbi.nlm.nih.gov/pubmed/36048026). 
    * Jain MD, Ziccheddu B, Coughlin CA, Faramand RG, Griswold AJ, Reid KM, Menges M, Zhang Y, Cen L, Wang X, Hussaini MO, Landgren O, Davila ML, Schatz JH, Locke FL, Maura F. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022 Aug.140(5):491-503. Pubmedid: [35476848](https://www.ncbi.nlm.nih.gov/pubmed/35476848). Pmcid: PMC9353150. 
    * Eriksen-Gjerstad M, Tveit Karlsen I, Fandalyuk Z, Benjaminsen S, Baran-Marszak F, Papp B, Locke F, Ladds M, Pastor-Fernández A, Gelebart P, Mc Cormack E. Dihydroorotate dehydrogenase inhibition acts synergistically with tyrosine kinase inhibitors to induce apoptosis of mantle cell lymphoma cells. EJHaem. 2022 Aug.3(3):913-918. Pubmedid: [36051066](https://www.ncbi.nlm.nih.gov/pubmed/36051066). Pmcid: PMC9422018. 
    * Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplant Cell Ther. 2022 Aug.28(8):487.e1-487.e7. Pubmedid: [35609865](https://www.ncbi.nlm.nih.gov/pubmed/35609865). Pmcid: PMC9375438. 
    * Cortes A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplant Cell Ther. 2021 Sep.27(9):768.e1-768.e6. Pubmedid: [34077811](https://www.ncbi.nlm.nih.gov/pubmed/34077811). Pmcid: PMC8403629. 
    * Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob AP, Mullins CD, Lee LW, Kong KA, Craig J, Mackall CL, Rapoport AP, Jain MD, Dahiya S, Locke FL, Miklos DB. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. J Clin Oncol. 2021 Sep.39(27):3034-3043. Pubmedid: [34133196](https://www.ncbi.nlm.nih.gov/pubmed/34133196). 
    * Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies. Transplant Cell Ther. 2021 Sep.27(9):720-728. Pubmedid: [34452722](https://www.ncbi.nlm.nih.gov/pubmed/34452722). Pmcid: PMC8447221. 
    * Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan P, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021 Sep.138(12):1081-1085. Pubmedid: [34041526](https://www.ncbi.nlm.nih.gov/pubmed/34041526). Pmcid: PMC8462361. 
    * Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan P, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste EW, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 Oct.5(20):4149-4155. Pubmedid: [34478487](https://www.ncbi.nlm.nih.gov/pubmed/34478487). Pmcid: PMC8945634. 
    * Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021 Oct.96(10):1295-1312. Pubmedid: [34310745](https://www.ncbi.nlm.nih.gov/pubmed/34310745). Pmcid: PMC9290945. 
    * Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021 Oct.9(10). Pubmedid: [34706886](https://www.ncbi.nlm.nih.gov/pubmed/34706886). Pmcid: PMC8552146. 
    * Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: [34329754](https://www.ncbi.nlm.nih.gov/pubmed/34329754). 
    * Jain MD, Locke FL. Seeing the Light: CAR T-cell Targeting of Lambda-restricted B-cell Lymphomas. Clin Cancer Res. 2021 Nov.27(21):5736-5738. Pubmedid: [34417197](https://www.ncbi.nlm.nih.gov/pubmed/34417197). 
    * Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 Nov.27(11):885-907. Pubmedid: [34461278](https://www.ncbi.nlm.nih.gov/pubmed/34461278). Pmcid: PMC8556300. 
    * Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 Nov.27(11):911.e1-911.e7. Pubmedid: [34450333](https://www.ncbi.nlm.nih.gov/pubmed/34450333). Pmcid: PMC8556305. 
    * Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: [33512407](https://www.ncbi.nlm.nih.gov/pubmed/33512407). Pmcid: PMC8120145. 
    * Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar.10(6):1936-1943. Pubmedid: [33641257](https://www.ncbi.nlm.nih.gov/pubmed/33641257). Pmcid: PMC7957158. 
    * Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: [33635333](https://www.ncbi.nlm.nih.gov/pubmed/33635333). Pmcid: PMC7948297. 
    * Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: [33781520](https://www.ncbi.nlm.nih.gov/pubmed/33781520). 
    * Kimmel GJ, Locke FL, Altrock PM. The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. Proc Biol Sci. 2021 Mar.288(1947):20210229. Pubmedid: [33757357](https://www.ncbi.nlm.nih.gov/pubmed/33757357). Pmcid: PMC8059581. 
    * Cornell RF, Bishop MR, Kumar S, Giralt SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZ. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. Am J Cancer Res. 2021 Jun.11(6):3285-3293. Pubmedid: [34249462](https://www.ncbi.nlm.nih.gov/pubmed/34249462). Pmcid: PMC8263642. 
    * Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: [33798768](https://www.ncbi.nlm.nih.gov/pubmed/33798768). 
    * Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, Pidala J, Achille A, Powers J, Sahakian E, Thapa R, Wang X, Anasetti C. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021 Jul.5(13):2740-2750. Pubmedid: [34242388](https://www.ncbi.nlm.nih.gov/pubmed/34242388). Pmcid: PMC8288668. 
    * Guerrouahen B, Elnaggar M, Al-Mohannadi A, Kizhakayil D, Bonini C, Benjamin R, Brentjens R, Buchholz CJ, Casorati G, Ferrone S, Locke FL, Martin F, Schambach A, Turtle C, Veys P, van der Vliet HJ, Maccalli C. Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar. Front Immunol. 2021 Jan.11:589381. Pubmedid: [33584653](https://www.ncbi.nlm.nih.gov/pubmed/33584653). Pmcid: PMC7874217. 
    * Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021 Jan.24(1):458-468. Pubmedid: [33691581](https://www.ncbi.nlm.nih.gov/pubmed/33691581). 
    * Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, Nishihori T, Perez L, Wang X, Anasetti C, Jim H. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021 Dec.56(12):2897-2903. Pubmedid: [34381169](https://www.ncbi.nlm.nih.gov/pubmed/34381169). 
    * Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. Int J Radiat Oncol Biol Phys. 2021 Dec.111(5):1145-1154. Pubmedid: [34242714](https://www.ncbi.nlm.nih.gov/pubmed/34242714). Pmcid: PMC9791939. 
    * Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021 Dec.56(12):2911-2921. Pubmedid: [34413469](https://www.ncbi.nlm.nih.gov/pubmed/34413469). Pmcid: PMC8639670. 
    * Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021 Dec.138(24):2499-2513. Pubmedid: [34166502](https://www.ncbi.nlm.nih.gov/pubmed/34166502). Pmcid: PMC8893508. 
    * Barata A, Hoogland AI, Hyland KA, Otto AK, Kommalapati A, Jayani RV, Irizarry-Arroyo N, Collier A, Rodriguez Y, Welniak TL, Booth-Jones M, Logue J, Small BJ, Jain MD, Reblin M, Locke FL, Jim HSL. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. Psychooncology. 2021 Aug.30(8):1294-1301. Pubmedid: [33739548](https://www.ncbi.nlm.nih.gov/pubmed/33739548). Pmcid: PMC9828891. 
    * Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: [32327504](https://www.ncbi.nlm.nih.gov/pubmed/32327504). Pmcid: PMC8017820. 
    * Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021 Apr.137(13):1832-1835. Pubmedid: [33156925](https://www.ncbi.nlm.nih.gov/pubmed/33156925). Pmcid: PMC8555382. 
    * Locke FL. Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?. Biol Blood Marrow Tr. 2020 Sep.26(9):e211-e212. Pubmedid: [32682950](https://www.ncbi.nlm.nih.gov/pubmed/32682950). 
    * Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: [32669372](https://www.ncbi.nlm.nih.gov/pubmed/32669372). Pmcid: PMC7501265. 
    * Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: [32877523](https://www.ncbi.nlm.nih.gov/pubmed/32877523). Pmcid: PMC7479945. 
    * Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep.38(27):3119-3128. Pubmedid: [32401634](https://www.ncbi.nlm.nih.gov/pubmed/32401634). Pmcid: PMC7499611. 
    * Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biol Blood Marrow Tr. 2020 Sep.26(9):1581-1588. Pubmedid: [32561336](https://www.ncbi.nlm.nih.gov/pubmed/32561336). 
    * Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Oct.4(19):4898-4911. Pubmedid: [33035333](https://www.ncbi.nlm.nih.gov/pubmed/33035333). Pmcid: PMC7556133. 
    * Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov.4(21):5414-5424. Pubmedid: [33147337](https://www.ncbi.nlm.nih.gov/pubmed/33147337). Pmcid: PMC7656920. 
    * Alvi RM, Fradley MG, Frigault MJ, Locke FL, Neilan TG. Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase Perspective. J Am Coll Cardiol. 2020 May.75(19):2523-2524. Pubmedid: [32408985](https://www.ncbi.nlm.nih.gov/pubmed/32408985). 
    * Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos D, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020 Jun.135(23):2106-2109. Pubmedid: [32181801](https://www.ncbi.nlm.nih.gov/pubmed/32181801). Pmcid: PMC7273828. 
    * Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea E, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 Jun.135(24):2182-2191. Pubmedid: [32478814](https://www.ncbi.nlm.nih.gov/pubmed/32478814). Pmcid: PMC7290092. 
    * Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Jul.4(14):3268-3276. Pubmedid: [32702097](https://www.ncbi.nlm.nih.gov/pubmed/32702097). Pmcid: PMC7391155. 
    * Frairia C, Nicolosi M, Shapiro J, Kim J, Betts BC, Fernandez HF, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C. Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease. Biol Blood Marrow Tr. 2020 Jul.26(7):1303-1311. Pubmedid: [32361010](https://www.ncbi.nlm.nih.gov/pubmed/32361010). Pmcid: PMC7771266. 
    * Locke FL, Go WY, Neelapu SS. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. JAMA Oncol. 2020 Feb.6(2):281-290. Pubmedid: [31697310](https://www.ncbi.nlm.nih.gov/pubmed/31697310). Pmcid: PMC7859915. 
    * Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 Dec.8(2). Pubmedid: [33335028](https://www.ncbi.nlm.nih.gov/pubmed/33335028). Pmcid: PMC7745688. 
    * Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma". Biol Blood Marrow Tr. 2020 Dec.26(12):e335-e336. Pubmedid: [32950694](https://www.ncbi.nlm.nih.gov/pubmed/32950694). 
    * Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020 Apr.4(7):1432-1439. Pubmedid: [32271899](https://www.ncbi.nlm.nih.gov/pubmed/32271899). Pmcid: PMC7160283. 
    * Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020 Apr.382(14):1331-1342. Pubmedid: [32242358](https://www.ncbi.nlm.nih.gov/pubmed/32242358). Pmcid: PMC7731441. 
    * Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020 Apr.4(7):1440-1447. Pubmedid: [32271898](https://www.ncbi.nlm.nih.gov/pubmed/32271898). Pmcid: PMC7160265. 
    * Kharfan-Dabaja MA, Jain MD, Aulakh S, Ayala E, Zubair AC, Tun HW, Liu HD, Locke FL, Chavez JC. Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. Am J Hematol. 2019 Sep.94(9):E245-E247. Pubmedid: [31211433](https://www.ncbi.nlm.nih.gov/pubmed/31211433). Pmcid: PMC6917994. 
    * Hashmi H, Bachmeier C, Chavez JC, Song J, Hussaini M, Krivenko G, Nishihori T, Kotani H, Davila ML, Locke FL, Jain MD. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. Brit J Haematol. 2019 Oct.187(2):e35-e38. Pubmedid: [31410842](https://www.ncbi.nlm.nih.gov/pubmed/31410842). 
    * Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Tr. 2019 Nov.25(11):e344-e351. Pubmedid: [31279751](https://www.ncbi.nlm.nih.gov/pubmed/31279751). Pmcid: PMC7800228. 
    * Locke FL. Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2019 May.17 Suppl 10(5):20-23. Pubmedid: [32720926](https://www.ncbi.nlm.nih.gov/pubmed/32720926). 
    * Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Ne. 2019 Mar.17(3):255-289. Pubmedid: [30865922](https://www.ncbi.nlm.nih.gov/pubmed/30865922). 
    * Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Hepatic veno-occlusive disease following sirolimus-based immune suppression. Bone Marrow Transplant. 2019 Jan.54(1):85-89. Pubmedid: [29895929](https://www.ncbi.nlm.nih.gov/pubmed/29895929). 
    * Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan.20(1):31-42. Pubmedid: [30518502](https://www.ncbi.nlm.nih.gov/pubmed/30518502). Pmcid: PMC6733402. 
    * Dholaria BR, Bachmeier CA, Locke F. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. BioDrugs. 2019 Feb.33(1):45-60. Pubmedid: [30560413](https://www.ncbi.nlm.nih.gov/pubmed/30560413). Pmcid: PMC6733400. 
    * Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019 Dec.74(25):3099-3108. Pubmedid: [31856966](https://www.ncbi.nlm.nih.gov/pubmed/31856966). Pmcid: PMC6938409. 
    * Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019 Dec.105(5):1012-1021. Pubmedid: [31175906](https://www.ncbi.nlm.nih.gov/pubmed/31175906). Pmcid: PMC6872916. 
    * Ruella M, Locke FL. Beat pediatric ALL MRD: CD28 CAR T and transplant. Blood. 2019 Dec.134(26):2333-2335. Pubmedid: [31877213](https://www.ncbi.nlm.nih.gov/pubmed/31877213). Pmcid: PMC6933292. 
    * Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months after autologous transplantation for newly diagnosed multiple myeloma. biol blood marrow tr. 2019 apr.254:683-688. pubmedid:>[30579965](https://www.ncbi.nlm.nih.gov/pubmed/30579965). Pmcid: PMC6453717. 
    * Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Tr. 2019 Apr.25(4):625-638. Pubmedid: [30592986](https://www.ncbi.nlm.nih.gov/pubmed/30592986). 
    * Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, Anasetti C. Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplant. 2018 Nov.53(11):1434-1444. Pubmedid: [29670210](https://www.ncbi.nlm.nih.gov/pubmed/29670210). Pmcid: PMC7771280. 
    * Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C. IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018 Mar.103(3):531-539. Pubmedid: [29242294](https://www.ncbi.nlm.nih.gov/pubmed/29242294). Pmcid: PMC5830373. 
    * Chavez JC, Locke FL. CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol. 2018 Jun.31(2):135-146. Pubmedid: [29909914](https://www.ncbi.nlm.nih.gov/pubmed/29909914). Pmcid: PMC6716161. 
    * Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan.15(1):47-62. Pubmedid: [28925994](https://www.ncbi.nlm.nih.gov/pubmed/28925994). Pmcid: PMC6733403. 
    * Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan.18(1):e35-e39. Pubmedid: [29126867](https://www.ncbi.nlm.nih.gov/pubmed/29126867). Pmcid: PMC6716154. 
    * Locke FL, Anasetti C. Off-the-shelf TCR for graft-versus-leukemia without GVHD. Blood. 2018 Jan.131(1):5-7. Pubmedid: [29301771](https://www.ncbi.nlm.nih.gov/pubmed/29301771). Pmcid: PMC5755047. 
    * Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2018 Feb.24(2):400-405. Pubmedid: [29032266](https://www.ncbi.nlm.nih.gov/pubmed/29032266). 
    * Locke FL, Haroun F. Advances in aggressive lymphoma from the 2017 American Society of Hematology Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol. 2018 Feb.16 Suppl 5(2):19-23. Pubmedid: [29742098](https://www.ncbi.nlm.nih.gov/pubmed/29742098). 
    * Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CA, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CA, Anasetti C. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Front Immunol. 2018 Dec.9:2887. Pubmedid: [30574153](https://www.ncbi.nlm.nih.gov/pubmed/30574153). Pmcid: PMC6291501. 
    * Locke FL, Jain MD. Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary. Clin Adv Hematol Oncol. 2018 Aug.16 Suppl 14(8):20-23. Pubmedid: [30300338](https://www.ncbi.nlm.nih.gov/pubmed/30300338). 
    * Hampras SS, Locke FL, Chavez JC, Patel NS, Giuliano AR, Miller K, Gheit T, Tommasino M, Rollison DE. Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma. 2018 Apr.59(4):911-917. Pubmedid: [28679298](https://www.ncbi.nlm.nih.gov/pubmed/28679298). Pmcid: PMC6150603. 
    * Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 Apr.15(4):218. Pubmedid: [29434334](https://www.ncbi.nlm.nih.gov/pubmed/29434334). Pmcid: PMC6716606. 
    * Neelapu SS, Locke FL, Go WY. CAR T-Cell Therapy in Large B-Cell Lymphoma. N Engl J Med. 2018 03.378(11):1065. Pubmedid: [29539277](https://www.ncbi.nlm.nih.gov/pubmed/29539277). 
    * Chavez J, Locke FL. A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction. Mol Ther. 2017 Oct.25(10):2241-2243. Pubmedid: [28941574](https://www.ncbi.nlm.nih.gov/pubmed/28941574). Pmcid: PMC5628929. 
    * Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May.102(5):948-957. Pubmedid: [28104702](https://www.ncbi.nlm.nih.gov/pubmed/28104702). Pmcid: PMC5477614. 
    * Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2017 Mar.23(3):405-411. Pubmedid: [28007665](https://www.ncbi.nlm.nih.gov/pubmed/28007665). Pmcid: PMC6716167. 
    * Locke FL, Davila ML. Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. Expert Opin Biol Ther. 2017 Jun.17(6):659-661. Pubmedid: [28454503](https://www.ncbi.nlm.nih.gov/pubmed/28454503). 
    * Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul.52(7):1003-1009. Pubmedid: [28368376](https://www.ncbi.nlm.nih.gov/pubmed/28368376). Pmcid: PMC7771296. 
    * Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 Jul.5:59. Pubmedid: [28725432](https://www.ncbi.nlm.nih.gov/pubmed/28725432). Pmcid: PMC5514522. 
    * Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan.25(1):285-295. Pubmedid: [28129122](https://www.ncbi.nlm.nih.gov/pubmed/28129122). Pmcid: PMC5363293. 
    * Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec.377(26):2531-2544. Pubmedid: [29226797](https://www.ncbi.nlm.nih.gov/pubmed/29226797). Pmcid: PMC5882485. 
    * Locke FL. Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2017 Aug.15 Suppl 8(8):16-19. Pubmedid: [28837125](https://www.ncbi.nlm.nih.gov/pubmed/28837125). 
    * Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 07.5(1):59. Pubmedid: [28716155](https://www.ncbi.nlm.nih.gov/pubmed/28716155). Pmcid: PMC5514522. 
    * Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C. Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant. 2016 Feb.51(2):291-294. Pubmedid: [26457911](https://www.ncbi.nlm.nih.gov/pubmed/26457911). Pmcid: PMC5726387. 
    * Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec.22(12):2201-2207. Pubmedid: [27660169](https://www.ncbi.nlm.nih.gov/pubmed/27660169). 
    * Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug.47:78-83. Pubmedid: [27285853](https://www.ncbi.nlm.nih.gov/pubmed/27285853). 
    * Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. Bone Marrow Transplant. 2016 09.51(9):1256-1258. Pubmedid: [27088383](https://www.ncbi.nlm.nih.gov/pubmed/27088383). 
    * Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant. 2015 Nov.50(11):1487-1489. Pubmedid: [26301969](https://www.ncbi.nlm.nih.gov/pubmed/26301969). Pmcid: PMC4863975. 
    * Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C. Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. J Immunother Cancer. 2015 May.3:20. Pubmedid: [25992291](https://www.ncbi.nlm.nih.gov/pubmed/25992291). Pmcid: PMC4437443. 
    * Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, Nishihori T, Locke F, Anasetti C, Kharfan-Dabaja MA. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jun.15(6):335-340. Pubmedid: [25659459](https://www.ncbi.nlm.nih.gov/pubmed/25659459). 
    * Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Tr. 2015 Jun.21(6):1074-1082. Pubmedid: [25805300](https://www.ncbi.nlm.nih.gov/pubmed/25805300). Pmcid: PMC5757506. 
    * Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 2015 Jul.100(7):970-977. Pubmedid: [25840599](https://www.ncbi.nlm.nih.gov/pubmed/25840599). Pmcid: PMC4486232. 
    * Zimmerman A, Locke FL, Emole J, Rosa M, Horna P, Hoover S, Dayicioglu D. Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated Lesion. Cancer Control. 2015 Jul.22(3):369-373. Pubmedid: [26351895](https://www.ncbi.nlm.nih.gov/pubmed/26351895). 
    * Locke FL, Rollison DE, Sondak VK. Merkel cell carcinoma and immunosuppression: what we still need to know. J Natl Cancer Inst. 2015 Feb.107(2). Pubmedid: [25575646](https://www.ncbi.nlm.nih.gov/pubmed/25575646). 
    * Emole JN, Locke FL, Pinilla-Ibarz J. An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy. 2015 Apr.7(4):455-466. Pubmedid: [25917633](https://www.ncbi.nlm.nih.gov/pubmed/25917633). 
    * Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leuk Res. 2014 Oct.38(10):1165-1172. Pubmedid: [24889511](https://www.ncbi.nlm.nih.gov/pubmed/24889511). Pmcid: PMC4625795. 
    * Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan.49(1):11-16. Pubmedid: [23995098](https://www.ncbi.nlm.nih.gov/pubmed/23995098). 
    * Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013 Sep.5(9):1005-1020. Pubmedid: [23998734](https://www.ncbi.nlm.nih.gov/pubmed/23998734). Pmcid: PMC4905571. 
    * Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov.48(11):1437-1443. Pubmedid: [23771005](https://www.ncbi.nlm.nih.gov/pubmed/23771005). Pmcid: PMC4279870. 
    * Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar.48(3):346-350. Pubmedid: [22863723](https://www.ncbi.nlm.nih.gov/pubmed/22863723). Pmcid: PMC4500122. 
    * Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul.19(7):1087-1093. Pubmedid: [23632090](https://www.ncbi.nlm.nih.gov/pubmed/23632090). Pmcid: PMC4667782. 
    * Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013 Aug.191(4):1677-1685. Pubmedid: [23851688](https://www.ncbi.nlm.nih.gov/pubmed/23851688). Pmcid: PMC3759681. 
    * Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov.209(12):2157-2163. Pubmedid: [23129747](https://www.ncbi.nlm.nih.gov/pubmed/23129747). Pmcid: PMC3501351. 
    * Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec.97(12):1882-1889. Pubmedid: [22689677](https://www.ncbi.nlm.nih.gov/pubmed/22689677). Pmcid: PMC3590095. 
    * Locke FL, Morgan GJ. What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?. Hematology Am Soc Hematol Educ Program. 2012.2012:350-353. Pubmedid: [23233603](https://www.ncbi.nlm.nih.gov/pubmed/23233603). 
    * Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011 Sep.96(9):1351-1356. Pubmedid: [21565902](https://www.ncbi.nlm.nih.gov/pubmed/21565902). Pmcid: PMC3166106. 
    * Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Aug.17(8):1237-1244. Pubmedid: [21215811](https://www.ncbi.nlm.nih.gov/pubmed/21215811). Pmcid: PMC5735843. 
    * Locke F, Clark JI, Gajewski TF. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol. 2010 Feb.65(3):509-514. Pubmedid: [19597729](https://www.ncbi.nlm.nih.gov/pubmed/19597729). 
    * Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec.45(12):1692-1698. Pubmedid: [20208570](https://www.ncbi.nlm.nih.gov/pubmed/20208570). 
    * Zha Y, Shah R, Locke F, Wong A, Gajewski TF. Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb.331(1-2):94-102. Pubmedid: [18177887](https://www.ncbi.nlm.nih.gov/pubmed/18177887). Pmcid: PMC3278801. 
    * Mattison RJ, Ostler KR, Locke FL, Godley LA. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials. 2007 May.2(2):135-141. Pubmedid: [18473998](https://www.ncbi.nlm.nih.gov/pubmed/18473998). 
  * ## Grants
    * Title: Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison  
Award Number: 5R01CA244328-04  
Sponsor: National Cancer Institute (NCI)  
Jim, H. (PD/PI), Locke, F. (PD/PI)
    * Title: Accelerated Aging After Chimeric Antigen Receptor T-Cell Therapy (CART): Leveraging a Novel Population of Cancer Survivors to Elucidate Mechanisms of Dementia  
Award Number: 3R01CA244328-01A1S1  
Sponsor: National Cancer Institute (NCI)  
Jim, H. (PD/PI), Locke, F. (PD/PI)
    * Title: Clinical investigation to improve efficacy of CAR-T Cell Therapy for Large B Cell Lymphoma  
Award Number: 2334-21  
Sponsor: Blood Cancer United  
Locke, F. (PD/PI)
    * Title: Kite Collaboration Master Agreement  
Award Number: 18-0500  
Sponsor: Kite Pharma  
Locke, F. (PD/PI)
    * Title: Axi-cel product mitochondrial membrane potential, reactive oxygen species, and cellular metabolic function and their association with clinical outcomes  
Award Number: 18VA031-S10  
Sponsor: Kite Pharma  
Locke, F. (PD/PI)
    * Title: Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-C  
Award Number: 1 R01 CA276040-01A1  
Sponsor: National Cancer Institute (NCI)  
Locke, F. (PD/PI)
    * Title: Optimizing single cell sequencing to elucidate the relationship between response to brexucabtagene autoleucel (brexu-cel)and cellular determinants of exhaustion  
Award Number: 18VA031 SOW#2  
Sponsor: Kite Pharma  
Shah, B. (PD/PI), Locke, F. (Co-PD/PI), Yu, X. (Co-PD/PI)


## Find a Researcher Search
Program Select Cancer Biology and Evolution Program Cancer Epidemiology Program Molecular Medicine Program Health Outcomes & Behavior Program Immuno-Oncology Non-Programmatically Aligned
Department Select BioEngineering Biostatistics and Bioinformatics Cancer Epidemiology Metabolism and Physiology Drug Discovery Health Outcomes & Behavior Immunology Integrated Mathematical Oncology Machine Learning Molecular Oncology Tumor Microenvironment and Metastasis
Center of Excellence Select Center for Infection Research in Cancer DeBartolo Family Personalized Medicine Institute Evolutionary Therapy Lung Cancer Center of Excellence Melanoma Research Center of Excellence
Work Group Select Cancer Chemoprevention Research Interest Group Myeloma Systems Medicine Working Group Tobacco Research & Intervention Program
Keyword
Search
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center") [ ![](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-mobile-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center")
Our Mission
To contribute to the prevention and cure of cancer.
[Connect with a Cancer Expert](https://www.moffitt.org/eforms/patientregistrationform/)
[ ![Designated Comprehensive Cancer Center](https://www.moffitt.org/globalassets/images/logos/nci.png) ](https://www.moffitt.org/about-moffitt/nci-designation/?source=footer "Designated Comprehensive Cancer Center") [ ![Florida Health Cancer Center of Excellence](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/moffitt-cancer-center-of-excellence-2.png) ](https://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html "Florida Health Cancer Center of Excellence") [ ![Magnet Recognized](https://www.moffitt.org/globalassets/images/logos/magnet.png) ](https://www.moffitt.org/about-moffitt/medical/nursing/?source=footer "Magnet Recognized") [ ![National Comprehensive Cancer Network](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/nccn.png) ](https://www.nccn.org/patients/ "National Comprehensive Cancer Network")
Careers
    * [Careers at Moffitt](https://www.moffitt.org/careers/)
    * [Search Jobs](https://moffitt-cancer-center-careers.hctsportals.com/)
    * [Training & Education](https://www.moffitt.org/education/)


Emerging Cancer Therapies
    * [CAR T Therapy](https://www.moffitt.org/treatments/immunotherapy/car-t-therapy/)
    * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/)
    * [TIL Therapy](https://www.moffitt.org/treatments/immunotherapy/til-therapy/)


Cancers & Treatments
    * [Cancers We Treat](https://www.moffitt.org/cancers/)
    * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
    * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/)
    * [Treatments We Offer](https://www.moffitt.org/treatments/)


Get Involved
    * [Donate](https://fundraise.moffitt.org/give/563959/#!/donation/checkout)
    * [Volunteer](https://www.moffitt.org/give/get-involved/volunteer-your-time/)
    * [Ways to Give](https://www.moffitt.org/give/ways-to-give/)


Cancer Screening
    * [Head and Neck Cancer Screening](https://www.moffitt.org/diagnostic-services/cancer-screenings/head-and-neck-cancer-screening/)
    * [Lung CT Screening](https://www.moffitt.org/cancers/lung-cancer/lung-cancer-screening-and-surveillance-program/)
    * [Mammogram](https://www.moffitt.org/cancers/breast-cancer/diagnosis/screening/mammogram/)
    * [Skin Cancer Mole Patrol](https://www.moffitt.org/diagnostic-services/cancer-screenings/mole-patrol/)


Patients & Family
    * [Appointments](https://www.moffitt.org/eforms/patientregistrationform/)
    * [Find a Doctor](https://www.moffitt.org/find-a-doctor/)
    * [Insurance & Financial Info](https://www.moffitt.org/patient-family/insurance-financial-information/)
    * [Moffitt Blog for Patients](https://www.moffitt.org/taking-care-of-your-health/)
    * [Patient & Family Resources](https://www.moffitt.org/patient-family/)


About Moffitt
    * [About](https://www.moffitt.org/about-moffitt/)
    * [Community Benefit](https://www.moffitt.org/publications/community-benefit/)
    * [Patient Outcomes](https://www.moffitt.org/about-moffitt/outcomes/)
    * [Research](https://www.moffitt.org/research-science/)


Industry Partnerships
    * [Available Emerging Technologies](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/available-technologies/)
    * [Business of Biotech](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/business-of-biotech/)
    * [Cell Therapy Facility](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/cell-therapy-gene-engineering/)
    * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/)


Resources
    * [Calendar of Events](https://www.moffitt.org/calendar/)
    * [Endeavor](https://www.moffitt.org/endeavor/)
    * [Newsroom](https://www.moffitt.org/newsroom/)
    * [Partnerships](https://www.moffitt.org/about-moffitt/strategic-alliances-and-partnerships/)
    * [Publications](https://www.moffitt.org/publications/)


Call Today
[1-888-663-3488](tel:1-888-663-3488 "Call Today")
[ ](https://www.facebook.com/MoffittCancerCenter "Facebook") [ ](https://twitter.com/MoffittNews "Twitter") [ ](https://www.instagram.com/moffittcancercenter/ "Instagram") [ ](https://www.youtube.com/user/MoffittNews "YouTube")
[ Getting Here ](https://www.moffitt.org/locations-directions/) [ Patient Portal ](https://my.moffitt.org/?source=footer&_ga=2.263078223.2128654650.1660063894-1522311918.1659049215) [ Refer a Patient ](https://www.moffitt.org/eforms/referapatient/) [ Provider Portal ](https://rpp.moffitt.org/) [ Staff Login ](https://hlmconnect.moffitt.org/dana-na/auth/url_default/welcome.cgi?source=footer&_ga=2.192849257.2128654650.1660063894-1522311918.1659049215)
  * [Privacy Policy](https://www.moffitt.org/legal-statements-and-policies/privacy-policy/)
  * [Terms & Conditions](https://www.moffitt.org/terms-conditions/ "Terms & Condition")
  * [Unsubscribe](https://www.moffitt.org/eforms/unsubscribe/ "Unsubscribe")
  * [State Nonprofit Disclosures](https://www.moffitt.org/globalassets/pdfs/footer/state-registration-for-web.pdf "State Nonprofit Disclosures")
  * [Donor Privacy](https://www.moffitt.org/give/donor-privacy/ "Donor Privacy")
  * [Notice of Privacy Practices](https://www.moffitt.org/legal-statements-and-policies/notice-of-privacy-practices/ "Notice of Privacy Practices")
  * [Visitor Policy](https://www.moffitt.org/globalassets/pdfs/patient--family/preparing-for-your-appointment/visitation-and-family-presence-policy.pdf "Visitor Policy")
  * [Moffitt Masking Policy](https://www.moffitt.org/globalassets/pdfs/footer/ic-085-moffitt-masking-policy.pdf)
  * [Price Transparency](https://eforms.moffitt.org/Moffittcancercenter_standardcharges/593238634_H.-Lee-Moffitt-Cancer-Center-and-Research-Institute-Hospital,-Inc._standardcharges.json)
  * [Sitemap](https://www.moffitt.org/sitemap.xml)


©Copyright 2025 Moffitt Cancer Center
Discover More
  * [Individualized Cancer Treatment in Florida](https://moffitt.org/patient-family/)
  * [Cancer Second Opinion Appointment in Florida](https://moffitt.org/diagnostic-services/second-opinion/)
  * [Cancer Healthcare Professionals in Florida](https://moffitt.org/for-healthcare-professionals/)


### Cambiar el idioma
Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al [1-888-663-3488](tel:1-888-663-3488).
Gracias.
[Cancel | Cancelar](https://www.moffitt.org/research-science/researchers/frederick-locke) [OK](https://www.moffitt.org/research-science/researchers/frederick-locke)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Search
Menu
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/frederick-locke) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/frederick-locke) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/frederick-locke) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-31)
  * [Research](https://www.moffitt.org/research-science/researchers/frederick-locke) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [Training & Education](https://www.moffitt.org/research-science/researchers/frederick-locke) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)
  * [Give](https://www.moffitt.org/research-science/researchers/frederick-locke) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-63)


Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/frederick-locke/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/frederick-locke/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate")
[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)[Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)
  * [ Cancers ](https://www.moffitt.org/cancers/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-5)
  * [ Treatments ](https://www.moffitt.org/treatments/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-7)
  * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-9)
  * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-11)


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)[Cancers](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)
  * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
  * [Acute Myelogenous Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myelogenous Leukemia \(AML\)")
  * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
  * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
  * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
  * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
  * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
  * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
  * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
  * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
  * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
  * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
  * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
  * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
  * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
  * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
  * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
  * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
  * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
  * [Chronic Myelogenous Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myelogenous Leukemia \(CML\)")
  * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
  * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
  * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
  * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
  * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
  * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
  * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
  * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
  * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
  * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
  * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
  * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
  * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
  * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
  * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
  * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
  * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
  * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
  * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
  * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
  * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
  * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
  * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
  * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
  * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
  * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
  * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
  * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
  * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
  * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
  * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
  * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
  * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
  * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
  * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
  * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
  * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
  * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
  * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
  * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
  * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
  * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
  * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
  * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
  * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
  * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
  * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
  * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
  * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
  * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
  * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
  * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
  * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
  * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
  * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
  * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
  * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
  * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
  * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
  * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
  * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)[Treatments](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)
  * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
  * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
  * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
  * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
  * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
  * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
  * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
  * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
  * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
  * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
  * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
  * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
  * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
  * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
  * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
  * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
  * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
  * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
  * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
  * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
  * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
  * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)[Clinical Trials](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)
  * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
  * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
  * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
  * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
  * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
  * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)[Diagnostic Services](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-3)
  * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
  * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
  * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
  * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
  * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
  * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)[Patients & Families](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)
  * [ Patient & Family ](https://www.moffitt.org/patient-family/)
  * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-15)
  * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-17)
  * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-19)
  * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-21)
  * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-23)
  * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-25)
  * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-27)
  * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-29)


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[Preparing For Your Appointment](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
  * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
  * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
  * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
  * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
  * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
  * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
  * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
  * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
  * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
  * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
  * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
  * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[Insurance & Financial Information](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
  * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
  * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
  * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
  * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
  * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
  * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
  * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
  * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
  * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[Programs & Support Services](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
  * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
  * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
  * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
  * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
  * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
  * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
  * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
  * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[Patient and Family Centered Care](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
  * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
  * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
  * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
  * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
  * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[Cancer Survivorship](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[International Patient Services](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
  * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
  * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
  * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[Moffitt Virtual Care](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
  * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
  * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
  * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)[Inspiring Stories](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-13)
  * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
  * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
  * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
  * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
  * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
  * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
  * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
  * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
  * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
  * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
  * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
  * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
  * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
  * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
  * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
  * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
  * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
  * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
  * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
  * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
  * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
  * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
  * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
  * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
  * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
  * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
  * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
  * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
  * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
  * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
  * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
  * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
  * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
  * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
  * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
  * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
  * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
  * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
  * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
  * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
  * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
  * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
  * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
  * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
  * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
  * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
  * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
  * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
  * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
  * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
  * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
  * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
  * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
  * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
  * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
  * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
  * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
  * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
  * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
  * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
  * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
  * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
  * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
  * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
  * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
  * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
  * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
  * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
  * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
  * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
  * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
  * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
  * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
  * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
  * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
  * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
  * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
  * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
  * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
  * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
  * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
  * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
  * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
  * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
  * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
  * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
  * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
  * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
  * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
  * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
  * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
  * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
  * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
  * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
  * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
  * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
  * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
  * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
  * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
  * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
  * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
  * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
  * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
  * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
  * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
  * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
  * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
  * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
  * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
  * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)[For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)
  * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
  * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-33)
  * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
  * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-35)


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-31)[Clinical Programs and Services](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-31)
  * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
  * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
  * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
  * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
  * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
  * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
  * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
  * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
  * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
  * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
  * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
  * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
  * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
  * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
  * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
  * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
  * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
  * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
  * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
  * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
  * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
  * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
  * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
  * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
  * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
  * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-31)[Continuing Education](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-31)
  * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
  * [Multidisciplinary Programs](https://www.moffitt.org/for-healthcare-professionals/continuing-education/multidisciplinary-programs/ "Multidisciplinary Programs")
  * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)[Research](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)
  * [ Research Science ](https://www.moffitt.org/research-science/)
  * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-39)
  * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-41)
  * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-43)
  * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-45)
  * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-47)
  * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-49)
  * [ Administration ](https://www.moffitt.org/research-science/administration/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-51)


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)[Research Programs](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
  * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
  * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
  * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
  * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)[Divisions and Departments](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
  * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
  * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
  * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
  * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)[Centers and Institutes](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
  * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)[Community Outreach and Engagement](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
  * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
  * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
  * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
  * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
  * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
  * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)[Shared Resources](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
  * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
  * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
  * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
  * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
  * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
  * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
  * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
  * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
  * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
  * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
  * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
  * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)[Academic and Industry Partnerships](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
  * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)[Administration](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-37)
  * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)[Training & Education](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)
  * [ Education ](https://www.moffitt.org/education/)
  * [ Medical Education ](https://www.moffitt.org/education/medical-education/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-55)
  * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-57)
  * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-59)
  * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-61)
  * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)[Medical Education](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)
  * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
  * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
  * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)[Research Education and Training](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)
  * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
  * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
  * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
  * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
  * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
  * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
  * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
  * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)[Nursing Education](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)
  * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
  * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
  * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
  * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
  * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)[Health Professional Education](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-53)
  * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
  * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
  * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
  * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
  * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
  * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
  * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
  * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
  * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
  * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
  * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
  * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
  * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
  * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
  * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
  * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
  * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
  * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
  * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
  * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
  * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
  * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
  * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
  * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)[Give](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-1)
  * [ Give ](https://www.moffitt.org/give/)
  * [ Why Give? ](https://www.moffitt.org/give/why-give/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-65)
  * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-67)
  * [ Get Involved ](https://www.moffitt.org/give/get-involved/) [](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-69)


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-63)[Why Give?](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-63)
  * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
  * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
  * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
  * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
  * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
  * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-63)[Ways to Give](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-63)
  * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
  * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
  * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
  * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
  * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
  * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
  * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
  * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
  * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
  * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-63)[Get Involved](https://www.moffitt.org/research-science/researchers/frederick-locke#mm-63)
  * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
  * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
  * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
  * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
  * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
  * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
  * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")


[](https://www.moffitt.org/research-science/researchers/frederick-locke#page)
